THURSDAY, July 3, 2014 (HealthDay News) -- Beleodaq (belinostat)
has been approved by the U.S. Food and Drug Administration to treat
peripheral T-Cell lymphoma (PTCL), a rare and aggressive form of
non-Hodgkin lymphoma (cancer of the lymph nodes).
Some 70,800 Americans will be diagnosed with non-Hodgkin
lymphoma this year, of which up to 15 percent will be PTCL,
according to U.S. National Cancer Institute estimates.
Beleodaq is designed to inhibit immune cells called T-cells from
becoming cancerous, the FDA explained Thursday in a news release.
The drug is intended for people whose cancer has returned or who
didn't respond to a prior therapy, the agency said.
Beleodaq's safety and effectiveness were evaluated in clinical
studies involving 129 people with PTCL. All were treated with the
newly approved drug, and about 26 percent had their cancer
disappear or shrink, the FDA said.
The most common side effects noted were nausea, vomiting,
fatigue, fever and low red blood cell count (anemia).
Beleodaq is marketed by Spectrum Pharmaceuticals, based in
To learn more about this approval, visit the